Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","amount":"$58.8 million","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"},{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"Jaguar Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Napo Pharmaceuticals, a Jaguar Health Company, Submits Investigational New Drug (IND) Application to FDA for Microvillus Inclusion Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Napo Therapeutics

    Menu

    Napo Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Napo Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Napo Pharmaceuticals, a Jaguar Health Company, Submits Investigational New Drug (IND) Application to FDA for Microvillus Inclusion Disease

              Details:

              Mytesi (crofelemer) powder for oral solution inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes, which being investigated for the treatment of microvillus inclusion disease.

              Lead Product(s): Crofelemer

              Therapeutic Area: Genetic Disease Product Name: Mytesi

              Highest Development Status: IND Enabling Product Type: Small molecule

              Recipient: Jaguar Health

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Napo Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.

              Details:

              The company's initial focus is on clinical development and future registration in Europe of Mytesi (crofelemer) for two debilitating rare disease target indications: short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) with intestinal failure.

              Lead Product(s): Crofelemer

              Therapeutic Area: Gastroenterology Product Name: Mytesi

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: SPRIM Global Investments

              Deal Size: $58.8 million Upfront Cash: Undisclosed

              Deal Type: Private Placement February 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY